I can only report what the company said when I met with them about a year ago (prior to their initial deal). They claimed then that they had freedom to operate in their own niche, but that Weissman had the rest of the space (going after CD47 directly) locked up.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.